Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX, Pembrolizumab, and IMC-CS4 in Borderline Resectable Pancreatic Cancer
NCT03153410Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2018
- Primary completion
- Mar 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY3022855 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Number of Patients With a Treatment-related Immunologic Effect at 8 weeks and Safety of the Combination at 25 months. Started Sep 2018; status: completed.
02
Drugs
LY3022855
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03153410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153410.